source
- FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapyThe U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
- California Supreme Court rejects claim that Gilead must fast-track safer HIV drugThousands of patients sued Gilead Sciences, alleging the company was negligent for delaying a safer HIV medicine and that they suffered kidney injury and bone loss from the older drug. The Califor…